Haitong Securities Industry Seminar
11month29On [date], the industry seminar themed 'Compliance and Listing Practices of Pharmaceutical Enterprises under New Circumstances and Environments', hosted by the Healthcare Industry Group of the Investment Banking Committee of Haitong Securities, was successfully held at the Shanghai Haitong Bund Financial Plaza. The purpose of this event is to provide pharmaceutical enterprises with professional compliance and listing practice training and service resources through on-site exchanges and discussions involving experts and scholars within the pharmaceutical industry, senior executives of pharmaceutical companies, and capital market guests. It aims to help pharmaceutical enterprises better plan their compliance growth and future development paths in the capital market under the new regulatory situation and environment, thereby reducing the risks and opportunity costs associated with compliance and listing in the future.
This event has invited Lv Chao, who has long worked in China's pharmaceutical regulatory department and is currently a non-equity partner at Zhong Lun Law Firm,RDPACFormer Chair of the Compliance Working Group and current National Biopharmaceutical Enterprise PlatformESGShen Yanrong, Secretary-General of the Special Committee, Wang Youzhi, Director of Legal Affairs at Haisen Biotechnology, Xiong Chuan, Partner at Zhonglun Law Firm, and Liu Jing, Vice President of Investment at Qiming Venture Capital, among others, were specially invited as keynote speakers for the event.60Representatives from Yuji's biopharmaceutical enterprises and investment institutions attended this exchange event.
Frost & SullivanFrost & SullivanPartner and Managing Director of Frost & Sullivan Greater China Region, Co-founder of LeadLeoCEOYang Xiaocheng was invited to attend the seminar. Yang Xiaocheng shared with the audience at the conference the latest report released by Frost & Sullivan this year.2023Hong Kong stocks for the year18A &The Blue Book on the Development of the Biotechnology Industry in the Sci-tech Innovation Board Market (hereinafter referred to as the 'Blue Book') provides insights through analysis of Hong Kong stocks18AAs well as an introduction to biotech companies on the Sci-tech Innovation Board and a comparison of issuance data, it provided participating guests with a panoramic analysis of the capital market for biotech companies. On this basis, it shared its views on the future trend of listing paths for biotech companies.
Partner and Managing Director of Frost & Sullivan Greater China, Co-founder of LeadLeoCEOYang Xiaocheng
According to Yang Xiaocheng, the 'Blue Book' is divided into five chapters, covering Hong Kong stocks18A &Panoramic analysis of the biotech capital market on the Sci-tech Innovation Board, industry analysis of biotech companies18ABiotech company issuance data, Sci-tech innovation board biotech company issuance data, and Hong Kong stocks18A &Introduction to biotech companies listed on the Sci-tech Innovation Board.
Chapter 1 of the Blue Book: Hong Kong stocks18AIndex performance, market value, and sector breakdown of the biotech market on the Sci-Tech Innovation Board, company list,2023A detailed analysis is conducted on valuation levels, performance, investment and financing environment, and other information.
Chapter 2 of the 'Blue Book' conducts an in-depth analysis of the market scale and driving factors of biomedicine in China. It elaborates on small molecule chemical drugs, antibody drugs, human vaccines, nucleic acid drugs, peptide drugs, cell and gene therapy drugs, etc., from dimensions such as product characteristics, market scale, and development trends. It also analyzes five major hot tracks: anti-tumor drugs, digestive tract and metabolic drugs, cardiovascular drugs, systemic anti-infective drugs, and central nervous system drugs, explaining them from dimensions such as industry introduction, development drivers, development trends, and market scale.
Chapter 3 of the 'Blue Book' provides an in-depth analysis of the scale and driving factors of China's medical device market, focusing on in vitro diagnostic devices, medical imaging equipment, cardiovascular interventional devices, orthopedic devices, ophthalmic devices, dental devices, surgical robots, artificial intelligence (AIMedical imaging is elaborated from dimensions such as basic concepts, product features, market size, and development trends.
Sections 4 and 5 of the Blue Book discuss Hong Kong stocks18AAn in-depth analysis is conducted on the situations of the fifth batch of listed companies on the Sci-tech Innovation Board from three stages: pre-public offering, during public offering, and post-public offering, and18AAn introduction to biotech companies listed on the Sci-Tech Innovation Board has been provided. For more detailed content, please refer to the full report.
At the same time, the seminar also included roundtable discussions and interactive sessions. Yang Xiaocheng, together with Lv Chao, Shen Yanrong, Wang Youzhi, Liu Jing, and Mr. Shen Sheng, the director of the Healthcare Industry Group at Haitong Securities and a former clinical doctor at Zhongshan Hospital affiliated with Fudan University and the Children's Hospital affiliated with Fudan University, participated. Mr. Hu Xuan, the director of the Healthcare Industry Group at Haitong Securities and a sponsor representative, organized in-depth discussions at the roundtable forum and interactions with the audience. The discussions mainly revolved around topics such as the future regulatory environment changes for pharmaceutical companies, practical suggestions for improving compliance in biopharmaceutical companies, how local pharmaceutical companies can learn from foreign company compliance experiences, and how enhancing compliance can help improve the valuation of pharmaceutical companies.
Recommended Reading
